In the absence of a submission from the holder of the marketing authorisation, cinacalcet (Mimpara®) cannot be endorsed for use within NHS Wales for the reduction of hypercalcaemia in patients with primary hyperparathyroidism (HPT) for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.